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dementia, the perspective and inclusion of informal costs is essential. The research 
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Objectives: Estimating resource use [RU] in real life is an important part of health 
economic evaluations. RU data should reflect how patients are actually treated. In 
MDD, RU data are mostly obtained from expert opinion. Variability in RU may lead to 
uncertainty in health economic evaluations, but few published studies report these 
data in the detail needed. The present analysis reports RU data by depression health 
state from an observational study. MethOds: PERFORM (Prospective Epidemiological 
Research on Functioning Outcomes Related to Major depressive disorder) is a 2-year 
prospective observational study conducted in 5 Western-European countries. Two- and 
six-month RU were estimated by health state: remitters, non-remitters, patients in 
relapse or not. RU included visits to different health care professionals, hospitalization 
and sick leave. Results are reported for the whole study population and are also avail-
able by country (including the UK, for which EQ5-D-derived utilities are also available) 
and for subgroups (e. g., patients who switched antidepressants at baseline). Results: 
Of the 819 analysable patients at 2 months, 29% were in remission. Among patients 
with at least one visit, the frequency of visits to general practitioners, psychiatrists 
and psychotherapists was consistently lower for remitters versus non-remitters (1.8 
vs. 2.4, 2.2 vs. 2.4 and 2.6 vs. 3.1 respectively). Fourteen patients had at least one hos-
pitalisation. Sick leave was less frequent (14% vs. 27%) and shorter (34 vs. 41 days) for 
remitters versus non-remitters respectively. At 6 months, 19.3% of patients relapsed. 
RU were higher with more visits to psychiatrists, psychotherapists (4.0 vs. 2.7, 7.8 
vs. 5.5) for relapsed versus non-relapsed patients. cOnclusiOns: This first analysis 
provides European RU data in MDD. More information is expected at completion of 
the two-year follow-up and this study offers the possibility to describe RU by health 
states, countries and subgroups and assess their transferability to other countries.
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bAcKGROund And Objectives: Economic crisis in Greece has several social impli-
cations, as unemployment and poverty have largely increased during the past years. 
Since the onset of the economic crisis, suicides have marked a significant increase. 
Therefore, aim of this study is to investigate the relationship between suicides and 
the economic crisis and certain macroeconomic indices. MethOds: Annual suicide 
rates were obtained from the Hellenic Statistical Authority. Multiple linear regres-
sion analysis with Newey-West standard errors was carried out in order to examine 
the relationship between gender and age specific suicide rates and unemployment, 
GDP per capita and economic crisis (binary variable). Additionally, several statistical 
tests were conducted in order to examine the properties and the robustness of the 
model. Results: Unemployment appears as the major factor affecting suicides of 
men and women above the age of 15. However, gender and age-related differences are 
being observed. Unemployment is positively associated with the suicides of men aged 
15-24, 35-44, 55-64 years. Female suicides are also affected by unemployment, exclud-
ing the age groups of 35-44 and 45-54 years old. Interestingly, suicides of women aged 
between 45-54 and 55-64 were negatively associated with economic crisis. In the total 
population, unemployment has impact on suicides for 15-24, 35-44, 55-64 age groups, 
while economic crisis affects suicide rate in the age group of 25-34. In addition, GDP 
per capita is negatively associated with suicide rates for young men (aged under 24). 
The same effect is also observed for the young population in general. cOnclusiOns: 
The current economic turmoil in Greece affects suicides deaths. According to this 
analysis, unemployment is the main factor that determines age-specific rates and 
essentially point to the direction where measures should be taken in order to control 
suicides’ incidence and lessen the effect of economic crisis on health.
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Objectives: Population-based approaches to improving health are critical to con-
trolling rising health care costs. US Veterans represent an identifiable population of 
significant interest due to their unique occupational exposures. The objectives of this 
study is to characterize the mental health of a representative US sample specifically 
comparing: non-Veterans, Veterans receiving VA benefits and Veterans not receiving 
VA benefits. MethOds: A representative (U.S. ) sample of 2,000 individuals completed 
an online survey assessing their mental health (PHQ-2), Veteran status and receipt of 
Veteran Administration health care benefits. We conducted bivariate analyses among 
the entire population and multivariate logistic regression among 352 Veterans to 
assess the relationship between ones mental health (PHQ-2 score > = 3) and Veteran 
benefit enrollment status controlling for ones self-reported physical health, history 
of combat, awareness of Veteran Crisis Line and sociodemographic factors. Results: 
Overall 28% of Veterans scored positive for depressive symptom based on a score 
of 3 or greater on the PHQ-2 compared to 11% of non-Veterans. However, breaking 
Veterans into those enrolled and those not enrolled revealed that 38% of enrolled 
Veterans were positive compared to just 17% of non-enrolled Veterans. After removing 
insignificant and/or collinear variables from the logistic regression model, the final 
set of independent variables included Vets enrolled in VA benefits OR= 3.91 (1.93- 8.44), 
poor/fair physical health OR= 4.32 (1.98-9.68), age OR= 0.93 (0.91-0.95) and awareness 
of Veteran crisis line 3.12 (1.69- 5.97). cOnclusiOns: Younger veterans in poorer 
physical health whom are receiving VA benefits and are aware of the Veteran Crisis 
line are more likely to have depressive symptoms. Population based approaches to 
linkage between the pharmaceutical database and the SANIARP database, using 
anonymized patient code. Based on the date of the first prescription (index date) 
the following prescribing patterns have been defined: continuers (subjects with 
a gap < 30 days between two prescriptions on-going); intermittent (subjects with 
a gap> 30 days but that receive another prescription at index date); switchers 
(discontinuation of index drug and prescription of a new antipsychotic); add-on 
(addition of a new antipsychotic); as-needed (addition of a new antipsychotic for 
a limited period). Results: We identified 2,768 patients (44.5% females) with at 
least one prescription of atypical antipsychotics and with a diagnosis coded in 
the study period. Schizophrenia is the most frequent indication (31.1%) the most 
prescribed drug is olanzapine (29.1%), followed by risperidone (17.7%), quetiapine 
(13.4%), aripiprazole (12.5%), clozapine (10.3%) and asenapine (3.1%). About 70% of 
schizophrenic patients is treated with the same drug, 7.9% switch and 23.6% is in 
polytherapy. cOnclusiOns: The use of SANIARP, web- platform able to allow the 
systematic monitoring of prescribing patterns of drugs, is of primary importance 
for better health planning.
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Objectives: Major Depressive Disorders (MDD) guidelines recommend using 
antidepressants with dual mechanism-of-action (venlafaxine, duloxetine) when 
resistant to a prior course of Selective-Serotonin-Reuptake-Inhibitors (SSRI). Dose 
to use should be close to the DDD recommended by WHO. Routine clinical prac-
tice may be frequently far from guidelines. The aim was to ascertain the average 
maintenance daily dose (DD) of venlafaxine and duloxetine in the monotherapy 
of patients with MDD who showed resistance to a previous SSRI in routine medi-
cal practice in Spain. MethOds: Retrospective analysis extracting consecutively 
electronic medical records (EMR) of the BSA, a provider which health plan coverage 
includes near 120,000 inhabitants in Badalona (Spain). EMR of male/female patients, 
> 18 years, included in the chronic prescription follow up program, with a MDD 
ICD-9-CM code (296.2x/296.3x), and who were resistant to a previous SSRI course, 
were extracted for analysis. Resistant was defined as persistence of symptoms 
(score > 17 in the Hamilton-Depression scale and/or reduction lower than 30% of the 
baseline score). Maintenance DD was considered the dose repeated (refills) at least 
two time consecutively during the study period (years 2012-2013). Results: Three-
sixty-eight EMR [81% women, 60.3 (15.2) years] were extracted; 160 of duloxetine 
and 208 of venlafaxine. Average maintenance DD were 65mg/day and 117 mg/day 
for duloxetine and venlafaxine, respectively. Demographics, number of comorbidi-
ties or previous SSRI were not related with average dose. 86% of duloxetine EMR 
were prescribed the WHO DDD for this drug (60mg), while only 42% of venlafaxine 
received its WHO DDD (100mg), p< 0.001. Number of DDD per day were significantly 
higher with venlafaxine; 1.17 (1.10-1.23) vs. 1.09 (1.05-1.12), p= 0.049. cOnclusiOns: 
Routine medical practice average maintenance DD of venlafaxine and duloxetine in 
SSRI resistant subjects with MDD are different in terms of both their recommended 
doses in labelling or guidelines and in number of DDD per day.
PMH66
tHE HEaltH EconoMic iMPact of rEsourcE usE in dEMEntia:  
tHE ErlanGEr dEMEntia rEGistry (Edr)
Schaller S.U.1, Marinova-Schmidt V.1, Gobin J.1, Luttenberger K.2, Richter-Schmidinger T.3, 
Gräßel E.2, Maler J.M.3, Kornhuber J.3, Kolominsky-Rabas P.L.1
1Centre for Health Technology Assessment (HTA) and Public Health (IZPH), Friedrich-Alexander-
University Erlangen-Nürnberg, Erlangen, Germany, 2Centre for Health Services Research in 
Medicine, Psychiatric and Psychotherapeutic Clinic, University Hospital, Friedrich-Alexander-
University Erlangen-Nürnberg, Erlangen, Germany, 3Psychiatric and Psychotherapeutic Clinic, 
University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, 
Germany
Objectives: Dementia patients are in need of more extensive personal care com-
pared to other long-term care users. This results in a high economic impact of demen-
tia on patients, families and health care systems. Due to the increasing prevalence 
of dementia worldwide, combined with limited health care expenditures, a better 
understanding of resource use in dementia care is needed. Therefore the aim of our 
study is the assessment of resource use in dementia in the most common setting: 
home-based care (informal caregivers). MethOds: The Erlanger Dementia Registry 
structure was set up in 2013. Both dementia patients and informal caregivers are 
interviewed separately with internationally approved valid instruments. Follow-up 
takes place after 6, 12 months and afterwards annually. Resource use in dementia is 
assessed via the ‘Resource Utilization in Dementia (RUD) instrument’. Results: A 
total number of 50 informal caregivers (mean age= 63, 61% female, 23% employed, 72% 
live together with the patient) were interviewed after the initial dementia diagnosis 
at baseline, and 22 study participants took part at the 1st follow-up. Informal caregiv-
ers were mainly spouses (72%) and children (22%). Main support was provided for 
instrumental activities of daily living (t0:77%; t6:86%), followed by activities of daily 
living (t0:37%; t6:52%) and supervision (t0:26%; t6:33%). Average hours for support 
6 months after diagnosis were: IADL= 4.3h/day (min= 1.0, max= 16.0), ADL= 5,2h/day 
(min= 2.0, max= 16.0), and supervision= 12.9h/day (min= 1.0, max= 24.0). The average 
monthly costs for informal caregivers 6 months after diagnosis (medication; addi-
tional disease-related costs) are 76 € . cOnclusiOns: Our results highlight the sig-
nificant impact of informal costs (time provided for care) in dementia care, occurring 
early in the disease course. For dementia patients cared for at home, informal costs 
put an additional economic burden on families. For future health policy planning in 
